A Stable and Scalable Digital Composite Neurocognitive Test for Early Dementia Screening Based on Machine Learning: Model Development and Validation Study.

"Conflicts of Interest: None declared."

"We thank all the researchers who helped with the data collection in the CN-NORM cohort. We also thank all the participants and their family members for their time and involvement in the CN-NORM cohort. This work was supported by the National Key Research and Development Program of China (grants #2018YFC1314200 and #2017YFC1311100), the Science and Technology Innovation 2030-Major Project (grant #2021ZD0201805), and the National Natural Science Foundation of China (grant #82271584). The funders were not involved in the study design, data collection, data analysis, and data interpretation, nor did they play a role in the writing of the manuscript and the decision to submit it for publication. The Alzheimer's Disease Neuroimaging Initiative (ADNI) data collection and sharing for this project was funded by the ADNI (National Institutes of Health grant #U01 AG024904) and the Department of Defense (award #W81XWH-12-2-0012). The ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc; Cogstate; Eisai Inc; Elan Pharmaceuticals, Inc; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc; Fujirebio; GE Healthcare; IXICO Ltd; Janssen Alzheimer Immunotherapy Research & Development, LLC; Johnson & Johnson Pharmaceutical Research & Development LLC; Lumosity; Lundbeck; Merck & Co, Inc; Meso Scale Diagnostics, LLC; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research provides funds to support ADNI clinical sites in Canada. ADNI investigators contributed to the design and implementation of the ADNI database or provided data but did not participate in the analysis or writing of this report. A complete listing of ADNI investigators is available [29]. Private sector contributions were facilitated by the Foundation for the National Institutes of Health. The grantee organization was the Northern California Institute for Research and Education, and the study was coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California."